Medication for Constipation

Marion Debus

Last update: 18.07.2019

  • In case of atony with too little propulsion:
    Bitter substances (e.g., Amara or Gentiana drops, see also https://www.anthromedics.org/PRA-0703-EN)

  • Especially with simultaneously occurring gas and bloating:
    Absinthium/Caryophylli comp. dil. WELEDA, 12 drops 3x/d
    Wormwood activates the peristalsis in the upper gastrointestinal tract, carnation seed essential oil has a warming effect, anise relaxes and regulates intestinal motility.

  • For constipation:
    Hepatodoron® tabs. WELEDA, 3x/d, chew 2–4 tabs. at the beginning of each meal

    Choleodoron® drops WELEDA, 10–20 drops 3x/d after meals

    Digestodoron® WELEDA, 3x/d, chew 2 tabs. at the beginning of each meal, or 15 drops 4x/d

  • In case of spastic constipation or chemotherapy-associated constipation (triggered by antiemetics from the serotonin antagonist family, whose symptoms can persist for several days, or even up to a week):
    Carpellum Mali comp. trit. WELEDA, 1 saltsp. (~¼ tsp.) 3–6/d after meals
    Start the day before chemotherapy with 1 generous salt spoon (or ¼ tsp.) to 1 teaspoon tip 3 x daily, then from the day of the chemotherapy onwards 1 generous salt spoon (~¼ tsp.) to 1 teaspoon tip 3–6 x daily. In the beginning it is more common to dose 6 x daily, then gradually reduce the amount, e.g., to 4 x daily, then 3 x daily, with dosing determined by stool frequency, whereby patients find their own dosage.

Research news

Phase IV trial: Kalium phosphoricum comp. versus placebo in irritability and nervousness 
In a new clinical study, Kalium phosphoricum comp. (KPC) versus placebo was tested in 77 patients per group. In a post-hoc analysis of intra-individual differences after 6 weeks treatment, a significant advantage of KPC vs. placebo was shown for characteristic symptoms of nervous exhaustion and nervousness (p = 0.020, p = 0.045 respectively). In both groups six adverse events (AE) were assessed as causally related to treatment (severity mild or moderate). No AE resulted in discontinuation in treatment. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia. The study has been published open access in Current Medical Research and Opinion
https://doi.org/10.1080/03007995.2023.2291169.


Further information on Anthroposophic Medicine